Ensuring the quality and efficacy of Haemophilus Influenzae b vac | 49367

Primary Health Care: Open Access

ISSN - 2167-1079

Ensuring the quality and efficacy of Haemophilus Influenzae b vaccines - The UK experience

9th Asia Pacific Global Summit on Healthcare & Immunology

July 03-05, 2017 Kuala Lumpur, Malaysia

Fatme Mawas

National Institute for Biological Standards & Control- MHRA, UK

Keynote: Primary Health Care

Abstract :

Haemophilus Influenzae type b (Hib) was a leading cause of meningitis in infants in the UK until October 1992, when Hib conjugate vaccine was introduced for children at age 2, 3, and 4 months. Quality control testing of the vaccine is very important to ensure the quality, safety and efficacy of the vaccine. Here, we describe our experience at the UK National Institute for Biological standards & Control in the testing and investigation of quality and efficacy of Hib vaccines in monovalent formulations and in combination with other vaccines such as meningococcal C or DTP-based combination vaccines.

Biography :

Fatme Mawas is an Immunologist/Microbiologist and completed her PhD in 1995 at King’s College (London). She is working as a Principal Scientist and Group Leader in Division of Bacteriology at NIBSC with 19-years of experience in the quality control and standardization of conjugate vaccines against Haemophilus influenzae type b, animal models and vaccine immunology. She has over 29 refereed papers covering various aspects of assay development, standardization and R&D in the field of conjugate vaccines, vaccine candidates and novel delivery systems.